Imaging Biomarkers of Adiposity and Sarcopenia as Potential Predictors for Overall Survival Among Patients with Endometrial Cancer Treated with Bevacizumab

ConclusionObesity has been associated with increased levels of vascular endothelial growth factor (VEGF), the main target for bevacizumab therapy. Imaging measurements of VFA may provide prognostic information for patients with EC but no adiposity marker was predictive of improved response to bevacizumab.
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research